Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer.

Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, Kagari T, Hirotani K, Yasunaga M, Matsumura Y, Doi T.

Mol Cancer Ther. 2019 Aug 8. pii: molcanther.0452.2019. doi: 10.1158/1535-7163.MCT-19-0452. [Epub ahead of print]

PMID:
31395690
2.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K.

J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.

3.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
4.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.

Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.

PMID:
30627987
5.

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis Refractory to Endoscopic Treatment with Dilatation in Patients Treated for Head and Neck Cancer.

Gusmon-Oliveira CC, Kuboki YM, de Paulo GA, de Lima MS, Uemura RS, Martins BC, Tolentino LL, Safatle-Ribeiro AV, Kulcsar MA, Ribeiro U Jr, Maluf-Filho F.

Gastroenterol Res Pract. 2018 Nov 12;2018:5428157. doi: 10.1155/2018/5428157. eCollection 2018.

6.

Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions.

Kuboki Y, Fischer CG, Beleva Guthrie V, Huang W, Yu J, Chianchiano P, Hosoda W, Zhang H, Zheng L, Shao X, Thompson ED, Waters K, Poling J, He J, Weiss MJ, Wolfgang CL, Goggins MG, Hruban RH, Roberts NJ, Karchin R, Wood LD.

J Pathol. 2019 Mar;247(3):347-356. doi: 10.1002/path.5194. Epub 2019 Jan 16.

PMID:
30430578
7.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma.

Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K.

ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018.

8.

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab.

Watanabe R, Nakano E, Kawazoe A, Kuboki Y, Bando H, Shitara K, Takahashi A, Tsutsumida A, Nishizawa A, Yamazaki N.

J Dermatol. 2019 May;46(5):e178-e180. doi: 10.1111/1346-8138.14693. Epub 2018 Oct 31. No abstract available.

PMID:
30379358
9.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

10.

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.

Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S, Yoshino T, Komatsu Y, Sakamoto N, Okamoto W, Fujii S.

Clin Colorectal Cancer. 2018 Sep;17(3):198-205. doi: 10.1016/j.clcc.2018.05.006. Epub 2018 May 19.

PMID:
29866615
11.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.

Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1.

PMID:
29859006
12.

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer.

Matsumoto H, Sasaki A, Nakamura Y, Kawazoe A, Kuboki Y, Okinaka K, Shitara K.

Case Rep Oncol. 2018 Apr 5;11(1):228-233. doi: 10.1159/000488313. eCollection 2018 Jan-Apr.

13.

Highly Discriminative and Chemoselective Deprotection/Transformations of Acetals with the Combination of Trialkylsilyl Triflate/2,4,6-Collidine.

Ohta R, Matsumoto N, Ueyama Y, Kuboki Y, Aoyama H, Murai K, Arisawa M, Maegawa T, Fujioka H.

J Org Chem. 2018 Jun 15;83(12):6432-6443. doi: 10.1021/acs.joc.8b00675. Epub 2018 Jun 7.

PMID:
29782161
14.

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.

Naito Y, Takahashi H, Shitara K, Okamoto W, Bando H, Kuwata T, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Watanabe A, Kojima M.

Jpn J Clin Oncol. 2018 Jun 1;48(6):559-564. doi: 10.1093/jjco/hyy052.

15.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.

Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K.

BMC Cancer. 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.

16.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
17.

Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report.

Fukuhara H, Kakizaki H, Kaneko H, Yamanobe T, Ushijima M, Kuboki Y, Tsuchiya N.

Urol Case Rep. 2017 Sep 8;15:11-13. doi: 10.1016/j.eucr.2017.08.001. eCollection 2017 Nov.

18.

In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.

Kuboki Y, Schatz CA, Koechert K, Schubert S, Feng J, Wittemer-Rump S, Ziegelbauer K, Krahn T, Nagatsuma AK, Ochiai A.

Gastric Cancer. 2018 May;21(3):401-412. doi: 10.1007/s10120-017-0758-x. Epub 2017 Aug 29.

19.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T.

Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28.

PMID:
28760399
20.

Gastrointestinal Perforation and Fistula Formation in 5 Patients With Colorectal Cancer During Treatment With Regorafenib.

Doi A, Kuboki Y, Shitara K, Fukuoka S, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2016 Dec 28. pii: S1533-0028(16)30257-2. doi: 10.1016/j.clcc.2016.11.003. [Epub ahead of print] No abstract available.

21.

[CEREBRAL VENOUS SINUS THROMBOSIS IN PATIENTS WITH METASTATIC TESTICULAR CANCER DURING CHEMOTHERAPY: REPORTS OF TWO CASES].

Kuboki Y, Yamagishi A, Kurokawa M, Kikuta M, Takai S, Takai Y, Ushijima M, Kurota Y, Yagi M, Sakurai T, Nishida H, Shibasaki T, Kawazoe H, Ichiyanagi O, Kato T, Nagaoka A, Tsuchiya N, Konno Y.

Nihon Hinyokika Gakkai Zasshi. 2017;108(4):225-228. doi: 10.5980/jpnjurol.108.225. Japanese.

22.

[A CASE OF BLEEDING AFTER PROSTATE BIOPSY WITH CONSERVATIVELY-TREATED GIANT RETROPERITONEAL HEMATOMA WHICH HAD EXTENDED INTRAPERITONEALLY].

Ozawa M, Kuboki Y, Suenaga S, Ishii T, Suzuki H, Tsuchiya N.

Nihon Hinyokika Gakkai Zasshi. 2017;108(2):114-117. doi: 10.5980/jpnjurol.108.114. Japanese.

23.

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.

Nagatani Y, Shitara K, Bando H, Kuboki Y, Okamoto W, Kojima T, Yoshino T, Nishida T, Ohtsu A, Doi T.

BMC Cancer. 2016 Nov 14;16(1):889.

24.

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.

Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2017 Jun;16(2):e39-e44. doi: 10.1016/j.clcc.2016.07.012. Epub 2016 Aug 18.

PMID:
27780748
25.

Clinicopathological features of programmed death ligandĀ 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.

Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A.

Gastric Cancer. 2017 May;20(3):407-415. doi: 10.1007/s10120-016-0631-3. Epub 2016 Sep 14.

PMID:
27629881
26.

Beckmann Fragmentation and Successive Carbon-Carbon Bond Formation Using Grignard Reagents via Phosphonium Salt Intermediates.

Fujioka H, Matsumoto N, Kuboki Y, Mitsukane H, Ohta R, Kimura T, Murai K.

Chem Pharm Bull (Tokyo). 2016;64(7):718-22. doi: 10.1248/cpb.c16-00006.

27.

Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.

Kotani D, Shitara K, Kawazoe A, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2016 Sep;15(3):e109-15. doi: 10.1016/j.clcc.2015.11.005. Epub 2015 Nov 27.

PMID:
26723516
28.

Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.

Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, Yoshino T, Doi T, Ochiai A, Ohtsu A.

Ann Oncol. 2016 Jan;27(1):127-33. doi: 10.1093/annonc/mdv508. Epub 2015 Oct 21.

PMID:
26489445
29.

TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.

Fujii S, Fujihara A, Natori K, Abe A, Kuboki Y, Higuchi Y, Aizawa M, Kuwata T, Kinoshita T, Yasui W, Ochiai A.

Cancer Med. 2015 Nov;4(11):1667-78. doi: 10.1002/cam4.515. Epub 2015 Sep 4.

30.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

31.

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.

Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.

PMID:
25777467
32.

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.

Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T.

Invest New Drugs. 2015 Jun;33(3):664-70. doi: 10.1007/s10637-015-0231-9. Epub 2015 Mar 15.

PMID:
25773493
33.

Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.

Furukawa T, Sakamoto H, Takeuchi S, Ameri M, Kuboki Y, Yamamoto T, Hatori T, Yamamoto M, Sugiyama M, Ohike N, Yamaguchi H, Shimizu M, Shibata N, Shimizu K, Shiratori K.

Sci Rep. 2015 Mar 6;5:8829. doi: 10.1038/srep08829.

34.

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.

Gastric Cancer. 2016 Jan;19(1):183-91. doi: 10.1007/s10120-015-0471-6. Epub 2015 Feb 15.

PMID:
25682441
35.

Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.

Kuboki Y, Shimizu K, Hatori T, Yamamoto M, Shibata N, Shiratori K, Furukawa T.

Pancreas. 2015 Mar;44(2):227-35. doi: 10.1097/MPA.0000000000000253.

PMID:
25423558
36.

Clustering of ant communities and indicator species analysis using self-organizing maps.

Park SH, Hosoishi S, Ogata K, Kuboki Y.

C R Biol. 2014 Sep;337(9):545-52. doi: 10.1016/j.crvi.2014.07.003. Epub 2014 Aug 10.

PMID:
25242693
37.

Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.

Sakamoto H, Kuboki Y, Hatori T, Yamamoto M, Sugiyama M, Shibata N, Shimizu K, Shiratori K, Furukawa T.

Mod Pathol. 2015 Feb;28(2):261-7. doi: 10.1038/modpathol.2014.98. Epub 2014 Aug 1.

38.

Effect of a tunnel-structured Ī²-tricalcium phosphate graft material on periodontal regeneration: a pilot study in a canine one-wall intrabony defect model.

Matsuura T, Akizuki T, Hoshi S, Ikawa T, Kinoshita A, Sunaga M, Oda S, Kuboki Y, Izumi Y.

J Periodontal Res. 2015 Jun;50(3):347-55. doi: 10.1111/jre.12213. Epub 2014 Jul 5.

PMID:
25040655
39.

Bone enhancing effect of titanium-binding proteins isolated from bovine bone and implanted into rat calvaria with titanium scaffold.

Kuboki Y, Furusawa T, Sato M, Sun Y, Unuma H, Abe S, Fujisawa R, Akasaka T, Watari F, Takita H, Sammons R.

Biomed Mater Eng. 2014;24(3):1539-48. doi: 10.3233/BME-140958.

PMID:
24840192
40.

Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer.

Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E, Mizunuma N, Ueno M, Yamaguchi T, Hatake K.

Anticancer Res. 2013 Sep;33(9):3905-10.

PMID:
24023327
41.

The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.

Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Furukawa T.

J Pathol. 2013 Nov;231(3):335-41. doi: 10.1002/path.4242.

PMID:
23893889
42.

Implantation with new three-dimensional porous titanium web for treatment of parietal bone defect in rabbit.

Guo Z, Iku S, Mu L, Wang Y, Shima T, Seki Y, Li Q, Kuboki Y.

Artif Organs. 2013 Jul;37(7):623-8. doi: 10.1111/aor.12058. Epub 2013 Apr 9.

PMID:
23565586
43.

Periodontal regeneration following application of basic fibroblast growth factor-2 in combination with beta tricalcium phosphate in class III furcation defects in dogs.

Saito A, Saito E, Kuboki Y, Kimura M, Nakajima T, Yuge F, Kato T, Honma Y, Takahashi T, Ohata N.

Dent Mater J. 2013;32(2):256-62.

44.

Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells.

Furukawa T, Tanji E, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shibata N, Shiratori K.

Mol Cancer. 2012 Dec 10;11:88. doi: 10.1186/1476-4598-11-88.

45.

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma.

Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E, Tsuyama N, Takeuchi K, Oguchi M, Hatake K.

Exp Hematol Oncol. 2012 Sep 24;1(1):30. doi: 10.1186/2162-3619-1-30.

46.

Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation.

Urata T, Naito Y, Nagamine M, Izumi Y, Tonaki G, Iwasaki H, Sasaki A, Yamasaki A, Minami N, Yoshioka R, Kitada H, Takekuma Y, Yokomizo H, Fukuda S, Yamaguchi H, Kuboki Y, Furukawa T, Hifumi M.

Clin J Gastroenterol. 2012 Dec;5(6):413-20. doi: 10.1007/s12328-012-0342-1. Epub 2012 Nov 15.

PMID:
26181322
47.

Interaction between titanium and phosphoproteins revealed by chromatography column packed with titanium beads.

Kuboki Y, Furusawa T, Sato M, Sun Y, Unuma H, Fujisawa R, Abe S, Akasaka T, Watari F, Takita H, Sammons R.

Biomed Mater Eng. 2012;22(5):283-8. doi: 10.3233/BME-2012-0718.

PMID:
23023145
48.

Periodontal repair following implantation of beta-tricalcium phosphate with different pore structures in Class III furcation defects in dogs.

Saito E, Saito A, Kuboki Y, Kimura M, Honma Y, Takahashi T, Kawanami M.

Dent Mater J. 2012;31(4):681-8.

49.

Three-dimensional geometry of honeycomb collagen promotes higher beating rate of myocardial cells in culture.

Guo Z, Iku S, Zheng X, Sammons RL, Kuboki Y.

Artif Organs. 2012 Sep;36(9):816-9. doi: 10.1111/j.1525-1594.2012.01446.x. Epub 2012 Apr 12.

PMID:
22497536
50.

[Pancreatic tumor: progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN); 2. Pathology and pathobiology].

Furukawa T, Kuboki Y, Hatori T, Yamamoto M, Shibata N, Shiratori K.

Nihon Naika Gakkai Zasshi. 2012 Jan 10;101(1):57-63. Japanese. No abstract available.

PMID:
22413462

Supplemental Content

Loading ...
Support Center